AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30275095 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatography-positive electrospray tandem mass spectrometry method used for analysis.
Number of subjects: 0
Study 27151271 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 698
Study 27151271 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 698
Study 25176293 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision at 1/2 of the urethral length
Number of subjects: 123
Study 25176293 — intervention group
Group type: COMPARATOR
Intervention: Incision at 1/3 of the urethral length
Number of subjects: 123
Study 25176293 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision at 1/2 of the urethral length (subgroup analysis for normal urethral mobility)
Number of subjects: 123
Study 25176293 — intervention group
Group type: COMPARATOR
Intervention: Incision at 1/3 of the urethral length (subgroup analysis for normal urethral mobility)
Number of subjects: 123
Study 22781507 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention
Number of subjects: 198
Study 21036512 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid maintenance medications
Number of subjects: 946
Study 21036512 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment programs
Number of subjects: 946
Study 18500098 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK surgery with the WaveLight ALLEGRETTO WAVE Excimer Laser System
Number of subjects: 151
Study 17006925 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil-tegafur (UFT) 300 mg/day for 1 year after surgery (n = 79)
Number of subjects: 160
Study 17006925 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group, n = 80)
Number of subjects: 160
Study 14583715 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mL 4% atomized lidocaine
Number of subjects: 30
Study 14583715 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mL 4% atomized cocaine
Number of subjects: 30
Study 14583715 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL 2% lidocaine gel
Number of subjects: 30
Study 10768306 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) treatment
Number of subjects: 131
Study 8648924 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 21
Study 8648924 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin (DD group)
Number of subjects: 21
Study 8648924 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin (SD group)
Number of subjects: 21
Study 8648924 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin (SD + C group)
Number of subjects: 21
Study 8648924 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 21
Study 1298089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef (125 mg mefloquine + 250 mg sulfadoxine + 12.5 mg pyrimethamine)
Number of subjects: 602
Study 1298089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lariam (125 mg mefloquine)
Number of subjects: 602
Study 1298089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansidar (500 mg sulfadoxine + 25 mg pyrimethamine)
Number of subjects: 602
Study 1298089 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (300 mg)
Number of subjects: 602
Study 1298089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 1298089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef
Number of subjects: 602
Study 1298089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lariam
Number of subjects: 602
Study 1298089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansidar
Number of subjects: 602
Study 1298089 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 602
Study 6094449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 142
Study 6094449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 142
Study 6094449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 142
Study 6094449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 30928620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (150 mg twice daily and 2 mg once daily respectively)
Number of subjects: 870
Study 30928620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study 30928620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 870
Study 29122646 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan
Number of subjects: 0
Study 29122646 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 26882500 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive Lifestyle Counseling program
Number of subjects: 175
Study 26882500 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 175
Study 25090110 — intervention group
Group type: EXPERIMENTAL
Intervention: HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine
Number of subjects: 186
Study 22733022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus flavopiridol (50 mg/m²/day, Arm A)
Number of subjects: 78
Study 22733022 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid flavopiridol (30 mg/m² over 30 min followed by 40 mg/m² over 4 h, Arm B)
Number of subjects: 78
Study 22733022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus flavopiridol (Arm A)
Number of subjects: 78
Study 22733022 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid flavopiridol (Arm B)
Number of subjects: 78
Study 22733022 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 78
Study 20854987 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic product containing Lactobacillus acidophilus CHO-220 and inulin
Number of subjects: 32
Study 17588490 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step-based drug treatment program (Treatment group)
Number of subjects: 315
Study 17588490 — intervention group
Group type: COMPARATOR
Intervention: Waiting List group
Number of subjects: 315
Study 17588490 — intervention group
Group type: COMPARATOR
Intervention: Community Control group
Number of subjects: 315
Study 17588490 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 315
Study 16320747 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and ultrashort‐wave treatment from the acute stage (Group A)
Number of subjects: 120
Study 16320747 — intervention group
Group type: COMPARATOR
Intervention: Ultrashort‐wave treatment at the acute stage and ultrashort‐wave plus electroacupuncture at the resting stage (Group B)
Number of subjects: 120
Study 16320747 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (Group A)
Number of subjects: 120
Study 11782652 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (2.5 g x kg(‐1) x d(‐1) CHO, 4.3 g x kg(‐1) x d(‐1) fat; FAT-adapt)
Number of subjects: 8
Study 11782652 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (9.3 g x kg(‐1) x d(‐1) CHO, 1.1 g x kg(‐1) x d(‐1) fat; HCHO)
Number of subjects: 8
Study 11782652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (FAT-adapt and HCHO)
Number of subjects: 8
Study 9718242 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion lessons (intervention group, high-risk; IGHR)
Number of subjects: 314
Study 9718242 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-risk; CGHR)
Number of subjects: 314
Study 9718242 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion lessons (HRf-IGHR)
Number of subjects: 314
Study 9718242 — intervention group
Group type: COMPARATOR
Intervention: Control group (HRf-CGHR)
Number of subjects: 314
Study 7853690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at 20 mg/kg
Number of subjects: 48
Study 7853690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at 40 mg/kg
Number of subjects: 48
Study 7853690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) in patients with purulent meningitis
Number of subjects: 48
Study 7853690 — intervention group
Group type: COMPARATOR
Intervention: Cefmetazole, ceftazidime, cefuzonam, flomoxef
Number of subjects: 48
Study 2582636 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 40
Study 2582636 — intervention group
Group type: COMPARATOR
Intervention: Control (no adenoidectomy)
Number of subjects: 40
Study 66871 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune serum globulin (antibody titer 1:355,000)
Number of subjects: 243
Study 66871 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gamma globulin (1:100)
Number of subjects: 243
Study 66871 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 243
Study 6101354 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin alone
Number of subjects: 13
Study 6101354 — intervention group
Group type: COMPARATOR
Intervention: Premarin plus norethisterone acetate
Number of subjects: 13
Study 6101354 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment equilin levels in group 1
Number of subjects: 13
Study 6101354 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment equilin levels in group 2
Number of subjects: 13
Study 30964969 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare DiamondClean Smart with Premium Plaque Control brush head (DCS)
Number of subjects: 219
Study 30964969 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B Genius 8000 with FlossAction brush head (OBG)
Number of subjects: 219
Study 30964969 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare DiamondClean Smart (DCS)
Number of subjects: 219
Study 30964969 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B Genius 8000 (OBG)
Number of subjects: 219
Study 27129571 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound-guided bilateral TAP block with 0.5 mL/kg of 0.25% bupivacaine
Number of subjects: 58
Study 27129571 — intervention group
Group type: COMPARATOR
Intervention: Control group received saline instead of bupivacaine
Number of subjects: 58
Study 27129571 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 58
Study 27129571 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 27345639 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate radiotherapy (21 Gy in three fractions within 42 days of the pleural intervention)
Number of subjects: 203
Study 27345639 — intervention group
Group type: COMPARATOR
Intervention: Deferred radiotherapy (same dose given within 35 days of PTM diagnosis)
Number of subjects: 203
Study 27345639 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate radiotherapy
Number of subjects: 203
Study 27345639 — intervention group
Group type: COMPARATOR
Intervention: Deferred radiotherapy
Number of subjects: 203
Study 24576799 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 830
Study 24576799 — intervention group
Group type: COMPARATOR
Intervention: Restricted approach (using clinical criteria to determine escalation of support)
Number of subjects: 830
Study 22008454 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 96
Study 22008454 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus calorie restriction (AEX + CR)
Number of subjects: 96
Study 19145644 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat exposure
Number of subjects: 2820
Study 19145644 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cohesion
Number of subjects: 2820
Study 19145644 — intervention group
Group type: COMPARATOR
Intervention: Baseline psychological symptoms
Number of subjects: 2820
Study 17595785 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum IGF-1 levels
Number of subjects: 0
Study 17595785 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-1 levels
Number of subjects: 0
Study 17595785 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1 expression in breast cancer tissue
Number of subjects: 0
Study 17595785 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying IGF-1 gene polymorphism
Number of subjects: 0
Study 15196523 — intervention group
Group type: EXPERIMENTAL
Intervention: VmaxST system
Number of subjects: 10
Study 15196523 — intervention group
Group type: COMPARATOR
Intervention: Douglas Bag method
Number of subjects: 10
Study 11222470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg TID (n=20)
Number of subjects: 39
Study 11222470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=19)
Number of subjects: 39
Study 9893547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 5 mg.ml‐1 with adrenaline 5 micrograms.ml‐1 (adrenaline group)
Number of subjects: 78
Study 9893547 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 5 mg.ml‐1 without adrenaline (plain group)
Number of subjects: 78
Study 7986965 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg b.d. for 6 days
Number of subjects: 12
Study 7986965 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.d. for 6 days
Number of subjects: 12
Study 2735519 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (0.5 mg terbutaline sulphate)
Number of subjects: 19
Study 2735519 — intervention group
Group type: COMPARATOR
Intervention: Metered Dose Inhaler (MDI) (0.5 mg terbutaline sulphate)
Number of subjects: 19
Study 1038622 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoded auditory information
Number of subjects: 180
Study 1038622 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded auditory information
Number of subjects: 180
Study 1038622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient auditory information
Number of subjects: 180
Study 31200823 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (icotinib plus pemetrexed and carboplatin)
Number of subjects: 179
Study 31200823 — intervention group
Group type: COMPARATOR
Intervention: Icotinib only group
Number of subjects: 179
Study 27865015 — intervention group
Group type: COMPARATOR
Intervention: Any cannabis use during treatment
Number of subjects: 1383
Study 27865015 — intervention group
Group type: COMPARATOR
Intervention: Second quartile of cannabis use (1-2 days per month)
Number of subjects: 1383
Study 27865015 — intervention group
Group type: COMPARATOR
Intervention: Any cannabis use or quartiles of cannabis use
Number of subjects: 1383
Study 25464828 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A‐tDCS) combined with F‐MP (motor practice inducing learning)
Number of subjects: 0
Study 25464828 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A‐tDCS) combined with S‐MP (motor practice not inducing learning)
Number of subjects: 0
Study 25464828 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation (Ctrl) combined with F‐MP
Number of subjects: 0
Study 25464828 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation (Ctrl) combined with S‐MP
Number of subjects: 0
Study 25464828 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor evoked potentials (MEPs) recorded before and after motor practice (TMS‐pre and TMS‐post)
Number of subjects: 0
Study 23644079 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg ∙ kg(‐1) ∙ day(‐1))
Number of subjects: 132
Study 23644079 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (immunosuppressant therapy only if corticosteroid dependency, chronic active disease, poor response to corticosteroids, or severe perianal disease)
Number of subjects: 132
Study 23644079 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 132
Study 23644079 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 132
Study 21078826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy with levo‐leucovorin + 5‐fluorouracil (5‐FU) + irinotecan (CPT‐11), administered every 2 weeks for 2 months on and 2 months off (arm A)
Number of subjects: 337
Study 21078826 — intervention group
Group type: COMPARATOR
Intervention: Continuous chemotherapy with levo‐leucovorin + 5‐fluorouracil (5‐FU) + irinotecan (CPT‐11), administered continuously (arm B)
Number of subjects: 337
Study 21078826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy (arm A)
Number of subjects: 337
Study 21078826 — intervention group
Group type: COMPARATOR
Intervention: Continuous chemotherapy (arm B)
Number of subjects: 337
Study 21078826 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line oxaliplatin-based treatment
Number of subjects: 337
Study 19402741 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity guidelines with varying frequency, intensity, duration, and mode
Number of subjects: 27
Study 19402741 — intervention group
Group type: COMPARATOR
Intervention: Factors unrelated to recommended guidelines
Number of subjects: 27
Study 17302722 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar, single site pacing with AF algorithm ON
Number of subjects: 72
Study 17302722 — intervention group
Group type: COMPARATOR
Intervention: Unipolar, single site pacing with AF algorithm OFF
Number of subjects: 72
Study 17302722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar, dual-site pacing with AF algorithm ON
Number of subjects: 72
Study 17302722 — intervention group
Group type: COMPARATOR
Intervention: Bipolar, dual-site pacing with AF algorithm OFF
Number of subjects: 72
Study 17302722 — intervention group
Group type: EXPERIMENTAL
Intervention: AF prevention algorithm ON
Number of subjects: 72
Study 15001789 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily additional sensorimotor stimulation of the arm for 6 weeks
Number of subjects: 100
Study 15001789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional stimulation)
Number of subjects: 100
Study 10744088 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alosetron orally twice daily for 12 weeks
Number of subjects: 647
Study 10744088 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally twice daily for 12 weeks
Number of subjects: 647
Study 10744088 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alosetron
Number of subjects: 647
Study 10744088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 647
Study 8759064 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (40 mg daily)
Number of subjects: 105
Study 8759064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 1349031 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha, 1.25-7.5 x 10(6) units/m2 subcutaneously three times/week
Number of subjects: 13
Study 4006661 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional instruction by a diabetes educator for 30 minutes
Number of subjects: 2
Study 4006661 — intervention group
Group type: COMPARATOR
Intervention: Self-instruction using written package instructions for 30 minutes
Number of subjects: 2
Study 30995176 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib (IDELA) 150 mg twice daily plus rituximab
Number of subjects: 110
Study 30995176 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus rituximab
Number of subjects: 110
Study 27889290 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical broccoli sprout extract (BSE) (500 nmol of sulforaphane/mL)
Number of subjects: 5
Study 27889290 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (placebo)
Number of subjects: 5
Study 25424047 — intervention group
Group type: EXPERIMENTAL
Intervention: Apitherapy
Number of subjects: 50
Study 25424047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23287903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver transfusion
Number of subjects: 106
Study 23287903 — intervention group
Group type: COMPARATOR
Intervention: Control (crystalloid or albumin for volume replacement and RBCs for anemia)
Number of subjects: 106
Study 21198375 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laparoscopic donor nephrectomy (group A)
Number of subjects: 50
Study 21198375 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site donor nephrectomy (group B)
Number of subjects: 50
Study 17638004 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching plus oral CDP‐choline (800 or 1,200 mg based on body weight) for 30 days
Number of subjects: 61
Study 17638004 — intervention group
Group type: COMPARATOR
Intervention: Patching alone for 30 days
Number of subjects: 61
Study 16889731 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous reduction and fixation
Number of subjects: 37
Study 16889731 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 37
Study 14570678 — intervention group
Group type: EXPERIMENTAL
Intervention: Group US (ultrasound-guided supraclavicular block)
Number of subjects: 80
Study 14570678 — intervention group
Group type: COMPARATOR
Intervention: Group NS (anatomical landmarks supraclavicular block)
Number of subjects: 80
Study 14570678 — intervention group
Group type: EXPERIMENTAL
Intervention: Group US
Number of subjects: 80
Study 14570678 — intervention group
Group type: COMPARATOR
Intervention: Group NS
Number of subjects: 80
Study 10340903 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of bleomycin‐etoposide‐cisplatin followed by two cycles of etoposide‐cisplatin with or without filgrastim
Number of subjects: 380
Study 10340903 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of bleomycin‐vincristine‐cisplatin followed by three cycles of etoposide‐ifosfamide‐cisplatin‐bleomycin with or without filgrastim
Number of subjects: 380
Study 7574020 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hetastarch plus 1 L lactated Ringer's solution (n = 20)
Number of subjects: 40
Study 7574020 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (n = 20)
Number of subjects: 40
Study 1662879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temafloxacin (600 mg b.i.d.)
Number of subjects: 374
Study 1662879 — intervention group
Group type: COMPARATOR
Intervention: Oral cefadroxil (500 mg b.i.d.)
Number of subjects: 374
Study 6128492 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 768
Study 6128492 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 768